Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ...

Rep. Jeff Hurd, the Republican representing Colorado’s 3rd Congressional District in the U.S. House of Representatives, ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

Reports as of December 31 the company had cash of $11.1M as of December 31, compared with $21.3M as of December 31, 2023. Subsequently, in ...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

A recent groundbreaking study published in Nature has opened a promising new chapter in the treatment of traumatic brain ...

On Feb. 24, a meeting was scheduled in Dolores that a staffer, Southwest Regional Director Naomi Dobbs, planned to attend. According to Cameryn Cass (Herald, Feb. 26) Dobbs fled the scene after ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...